Scinovex
erratum Open AccessTop 1% cited

The somatic mutation profiles of 2,433 breast cancers refine their genomic and transcriptomic landscapes

Nature Communications · 2016 · Vol. 7(1) · pp. 11479–11479
Bernard PereiraSuet‐Feung ChinOscar M. RuedaHans-Kristian Moen VollanElena ProvenzanoHelen BardwellMichelle PughLinda JonesRoslin RussellStephen‐John SammutDana W.Y. TsuiBin LiuSarah‐Jane DawsonJean AbrahamHelen NorthenJohn F. PedenAbhik MukherjeeGulisa TurashviliAndrew R. GreenSteve McKinneyArusha OloumiSohrab P. ShahNitzan RosenfeldLeigh C. MurphyDavid BentleyIan O. EllisArnie PurushothamSarah E. PinderAnne‐Lise Børresen‐DaleHelena EarlPaul D.P. PharoahMark T. RossSamuel AparícioCarlos Caldas

Abstract

The genomic landscape of breast cancer is complex, and inter- and intra-tumour heterogeneity are important challenges in treating the disease. In this study, we sequence 173 genes in 2,433 primary breast tumours that have copy number aberration (CNA), gene expression and long-term clinical follow-up data. We identify 40 mutation-driver (Mut-driver) genes, and determine associations between mutations, driver CNA profiles, clinical-pathological parameters and survival. We assess the clonal states of Mut-driver mutations, and estimate levels of intra-tumour heterogeneity using mutant-allele fractions. Associations between PIK3CA mutations and reduced survival are identified in three subgroups of ER-positive cancer (defined by amplification of 17q23, 11q13-14 or 8q24). High levels of intra-tumour heterogeneity are in general associated with a worse outcome, but highly aggressive tumours with 11q13-14 amplification have low levels of intra-tumour heterogeneity. These results emphasize the importance of genome-based stratification of breast cancer, and have important implications for designing therapeutic strategies.

Cancer Genomics and DiagnosticsGenomic variations and chromosomal abnormalitiesGenetic factors in colorectal cancerBreast cancerBiologyMutationTranscriptomeGeneGenetic heterogeneityAlleleGeneticsSomatic cellTumour heterogeneity

MeSH terms

AdultAgedBreast NeoplasmsFemaleHumansMiddle AgedMutationPrognosisProportional Hazards ModelsGenes, Tumor SuppressorKaplan-Meier EstimateGenetic Association StudiesDNA Copy Number VariationsClass I Phosphatidylinositol 3-KinasesTranscriptome

Funding

  • Cancer Research UK
  • National Institute for Health and Care Research
  • University of Cambridge
  • BC Cancer Agency
  • NIHR Cambridge Biomedical Research Centre
  • Cancer Research UK Cambridge Institute, University of Cambridge
Citations
1,777
FWCI
59.58
field-weighted impact
References
72
Percentile
100%
vs. same field & year
Citations per year
Cited by
The Landscape of Targeted Therapies in TNBC
Cancers · 2020 · 434 citations
Citation Network

How this paper connects to the literature. Drag to explore, click any node to open that paper.